91 research outputs found
Severe Coronavirus Disease 2019 Infection in an Adolescent Patient After Hematopoietic Stem Cell Transplantation
© 2020 American College of Chest Physicians Infection with the severe acute respiratory syndrome coronavirus 2 causes severe acute lung injury in approximately 5% of infected adults, but few reports have been made of severe pediatric disease. We present an adolescent patient who contracted severe acute respiratory syndrome coronavirus 2 one week after a paternal haplo-identical hematopoietic stem cell transplant, with development of severe hyperferritinemic acute lung injury and macrophage activation-like syndrome. We present her case and a comparison of her laboratory data with those of a cohort of pediatric patients with coronavirus disease 2019 without severe disease
Workshop Guide for Genealogy of Texts and Ideas
This is the workshop guide and presents a detail of how our workshop time was allocated
Effect of pollution control measures on the demand for fossil fuels in the middle Atlantic States.
Timing of Alemtuzumab with Respect to Day of Bone Marrow Infusion and its Effects upon Engraftment and Graft-Versus-Host Disease in Patients with Sickle Cell Disease: A Single-Institutional Study
© 2020 Wolters Kluwer Health, Inc. All rights reserved. The possible impact of late alemtuzumab (administered on days-10 to-8) versus early alemtuzumab (-19 to-17) with respect to engraftment and acute/chronic graft-versus-host disease (GvHD) in a group of 25 pediatric patients with sickle cell disease undergoing bone marrow transplantation following conditioning with alemtuzumab, fludarabine, and melphalan is reported. The first 9 patients received late alemtuzumab followed by bone marrow transplantation from HLA-matched sibling donors. The next 16 patients undergoing matched sibling transplants received early alemtuzumab. In the late group, 1 patient (11%) developed acute GvHD. Six patients (67%) achieved sustained engraftment. Three patients (33%) experienced graft rejection, leading to termination of enrollment of patients on this regimen. In the early alemtuzumab group, acute and chronic GvHD developed in 43% and 25% patients, respectively. None of the patients experienced graft rejection in this group of patients. Three patients developed stable mixed chimerism and 13 patients demonstrated 100% donor chimerism at 1 year post-transplant and beyond. These results suggest a benefit with respect to engraftment of administering early versus late alemtuzumab in this reduced-intensity conditioning regimen, however, with the possible cost of an increase in acute, and possibly chronic GvHD
Reduced Intensity Conditioning in Transplants for Patients with Sickle Cell Disease: Effect of “Late” Alemtuzumab
Exon 8 IL2RG Mutation Implicated in an Atypical Immunophenotype in a Newborn with X-SCID
Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).
- …